WallStreetZenWallStreetZen

NASDAQ: BOLD
Boundless Bio Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for BOLD

Based on 1 analyst offering 12 month price targets for Boundless Bio Inc

Min Forecast
$4.00+225.2%
Avg Forecast
$4.00+225.2%
Max Forecast
$4.00+225.2%

Should I buy or sell BOLD stock?

Based on 1 analyst offering ratings for Boundless Bio Inc.

Buy
Strong Buy
0 analysts 0%
Buy
1 analysts 100%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their BOLD stock forecasts and price targets.

BOLD stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-08-11

1 of 1

Forecast return on equity

Is BOLD forecast to generate an efficient return?

Company
N/A
Industry
248.3%
Market
228.5%

Forecast return on assets

Is BOLD forecast to generate an efficient return on assets?

Company
N/A
Industry
88.66%

BOLD earnings per share forecast

What is BOLD's earnings per share in the next 3 years based on estimates from 5 analysts?

Avg 1 year Forecast
-$2.52
Avg 2 year Forecast
-$2.15
Avg 3 year Forecast
-$1.05

BOLD revenue forecast

What is BOLD's revenue in the next 3 years based on estimates from 5 analysts?

Avg 1 year Forecast
$0.0
Avg 2 year Forecast
$0.0
Avg 3 year Forecast
$0.0

BOLD vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
BOLD$1.23$4.00+225.20%Buy
NERV$3.98$4.00+0.50%Hold
GNTA$1.47N/AN/A
CING$4.18$37.00+785.17%Strong Buy
SER$2.65$15.00+466.04%Buy
View Top Biotech Stocks

Boundless Bio Stock Forecast FAQ

Is Boundless Bio Stock a good buy in 2025, according to Wall Street analysts?

The consensus among 1 Wall Street analyst covering (NASDAQ: BOLD) stock is to Buy BOLD stock.

Out of 1 analyst, 0 (0%) are recommending BOLD as a Strong Buy, 1 (100%) are recommending BOLD as a Buy, 0 (0%) are recommending BOLD as a Hold, 0 (0%) are recommending BOLD as a Sell, and 0 (0%) are recommending BOLD as a Strong Sell.

If you're new to stock investing, here's how to buy Boundless Bio stock.

What is BOLD's earnings growth forecast for 2025-2027?

(NASDAQ: BOLD) Boundless Bio's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 42.81%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 42.51%.

Boundless Bio's earnings in 2025 is -$61,760,000.On average, 5 Wall Street analysts forecast BOLD's earnings for 2025 to be -$56,398,308, with the lowest BOLD earnings forecast at -$55,064,126, and the highest BOLD earnings forecast at -$57,586,984. On average, 5 Wall Street analysts forecast BOLD's earnings for 2026 to be -$48,026,090, with the lowest BOLD earnings forecast at -$55,064,126, and the highest BOLD earnings forecast at -$42,543,854.

In 2027, BOLD is forecast to generate -$23,442,212 in earnings, with the lowest earnings forecast at -$27,641,752 and the highest earnings forecast at -$17,158,571.

What is BOLD's revenue growth forecast for 2025-2027?

(NASDAQ: BOLD) Boundless Bio's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 98.52%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 25.72%.

Boundless Bio's revenue in 2025 is $0.On average, 5 Wall Street analysts forecast BOLD's revenue for 2025 to be $0, with the lowest BOLD revenue forecast at $0, and the highest BOLD revenue forecast at $0. On average, 5 Wall Street analysts forecast BOLD's revenue for 2026 to be $0, with the lowest BOLD revenue forecast at $0, and the highest BOLD revenue forecast at $0.

In 2027, BOLD is forecast to generate $0 in revenue, with the lowest revenue forecast at $0 and the highest revenue forecast at $0.

What is BOLD's forecast return on assets (ROA) for 2025-2028?

(NASDAQ: BOLD) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of 88.66%.

What is BOLD's Price Target?

According to 1 Wall Street analyst that have issued a 1 year BOLD price target, the average BOLD price target is $4.00, with the highest BOLD stock price forecast at $4.00 and the lowest BOLD stock price forecast at $4.00.

The Wall Street analyst predicted that Boundless Bio's share price could reach $4.00 by Aug 11, 2026. The average Boundless Bio stock price prediction forecasts a potential upside of 225.2% from the current BOLD share price of $1.23.

What is BOLD's Earnings Per Share (EPS) forecast for 2025-2027?

(NASDAQ: BOLD) Boundless Bio's current Earnings Per Share (EPS) is -$2.66. On average, analysts forecast that BOLD's EPS will be -$2.52 for 2025, with the lowest EPS forecast at -$2.46, and the highest EPS forecast at -$2.57. On average, analysts forecast that BOLD's EPS will be -$2.15 for 2026, with the lowest EPS forecast at -$2.46, and the highest EPS forecast at -$1.90. In 2027, BOLD's EPS is forecast to hit -$1.05 (min: -$1.23, max: -$0.77).

What is BOLD's forecast return on equity (ROE) for 2025-2028?

(NASDAQ: BOLD) forecast ROE is N/A, which is considered weak.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.